|
1) Turpie AG. New oral anticoagulants in atrial fibrillation. Eur Heart J. 2008; 29: 155-65
|
|
|
|
2) Hankey GJ, Eikelboom JW. Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events. Lancet Neurol. 2010; 9: 273-84
|
|
|
|
|
3) Steffel J, Braunwald E. Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism. Eur Heart J. 2011; 32: 1968-76
|
|
|
|
|
|
4) Gross PL, Weitz JI. New anticoagulants for treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol. 2008; 28: 380-6
|
|
|
|
|
|
5) Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thrombo-prophylaxis after hip arthroplasty. N Engl J Med. 2008; 358: 2765-75
|
|
|
|
|
|
6) Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008; 372: 31-9
|
|
|
|
|
|
7) Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thrombo-prophylaxis after total knee arthroplasty. N Engl J Med. 2008; 358: 2776-86
|
|
|
|
|
|
8) Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thrombo-prophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009; 373: 1673-80
|
|
|
|
|
|
9) Investigators RAS. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J. 2010; 159: 340-7
|
|
|
|
|
|
10) Gensch C, Hoppe U, Bohm M, et al. Late-breaking clinical trials presented at the American Heart Association Congress in Chicago 2010. Clin Res Cardiol. 2011; 100: 1-9
|
|
|
|
|
|
11) Mega JL, Braunwald E, Mohanavelu S, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet. 2009; 374: 29-38
|
|
|
|
|
|
12) Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010; 363: 2499-510
|
|
|
|
|
|
13) Cohen AT, Spiro TE, Buller HR, et al. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. J Thromb Thrombolysis. 2011; 31: 407-16
|
|
|
|
|
|
14) Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost. 2010; 104: 49-60
|
|
|
|
|
|
15) Lassen MR, Gallus A, Raskob GE, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010; 363: 2487-98
|
|
|
|
|
|
16) Lassen MR, Raskob GE, Gallus A, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010; 375: 807-15
|
|
|
|
|
|
17) Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011; 364: 806-17
|
|
|
|
|
|
18) Lopes RD, Alexander JH, Al-Khatib SM, et al. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J. 2010; 159: 331-9
|
|
|
|
|
|
19) Alexander JH, Becker RC, Bhatt DL, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009; 119: 2877-85
|
|
|
|
|
|
20) Fuji T, Fujita S, Tachibana S, et al. A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. J Thromb Haemost. 2010; 8: 2458-68
|
|
|
|
|
|
21) Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 2010; 160: 635-41
|
|
|
|
|
|
22) van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010; 103: 1116-27
|
|
|
|
|
|
23) Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007; 370: 949-56
|
|
|
|
|
|
24) Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007; 5: 2178-85
|
|
|
|
|
|
25) Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361: 1139-51
|
|
|
|
|